| Study of Verinurad in Heart Failure With Preserved Ejection Fraction (NCT04327024) | AstraZeneca | 2020-05-19 |
| An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients. (NCT03433924) | AstraZeneca | 2020-05-18 |
| Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects (NCT04362410) | AstraZeneca | 2020-05-18 |
| Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) (NCT06099067) | AstraZeneca | 2020-05-15 |
| Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (NCT04269200) | AstraZeneca | 2020-05-05 |
| Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies (NCT03932331) | AstraZeneca | 2020-04-29 |
| Development of AECOPD Identification Tool (DETECT Study) (NCT03556475) | AstraZeneca | 2020-04-28 |
| Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab. (NCT04381494) | AstraZeneca | 2020-04-27 |
| A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (NCT04214288) | AstraZeneca | 2020-04-22 |
| A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients (NCT03485326) | AstraZeneca | 2020-04-21 |
| Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (NCT04305496) | AstraZeneca | 2020-04-16 |
| To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. (NCT03658213) | AstraZeneca | 2020-03-31 |
| Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy (NCT04207775) | AstraZeneca | 2020-03-30 |
| Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients (NCT04222465) | AstraZeneca | 2020-03-19 |
| ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab (NCT04272463) | AstraZeneca | 2020-03-13 |
| Baxdrostat Bioavailability and Bioequivalence Study (NCT05963009) | AstraZeneca | 2020-03-11 |
| A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart (NCT04256629) | AstraZeneca | 2020-03-03 |
| Open-label Extension Study of Brazikumab in Ulcerative Colitis (NCT04277546) | AstraZeneca | 2020-03-03 |
| A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry. (NCT04269031) | AstraZeneca | 2020-02-13 |
| A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen (NCT04187508) | AstraZeneca | 2020-02-06 |
| Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS) (NCT04068168) | AstraZeneca | 2020-01-30 |
| Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers. (NCT04199598) | AstraZeneca | 2020-01-28 |
| Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia (NCT04075292) | AstraZeneca | 2020-01-20 |
| A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers (NCT04232345) | AstraZeneca | 2020-01-16 |
| Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours (NCT04236414) | AstraZeneca | 2020-01-14 |
| Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain (NCT04126499) | AstraZeneca | 2020-01-13 |
| Open-label Extension Study of Brazikumab in Crohn's Disease (NCT03961815) | AstraZeneca | 2020-01-06 |
| A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body (NCT04187456) | AstraZeneca | 2019-12-27 |
| Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium (NCT04221802) | AstraZeneca | 2019-12-23 |
| Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma (NCT04200326) | AstraZeneca | 2019-12-20 |
| Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects (NCT05500820) | AstraZeneca | 2019-12-19 |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors (NCT04214093) | AstraZeneca | 2019-12-16 |
| A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine (NCT04179071) | AstraZeneca | 2019-12-13 |
| A Study to Compare Severe Asthma Patients Who Start Biologics and Who do Not Start (PROSPECT) (NCT04808518) | AstraZeneca | 2019-12-10 |
| US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (NCT04125290) | AstraZeneca | 2019-12-09 |
| Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis (NCT04212169) | AstraZeneca | 2019-12-09 |
| An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients (NCT04072523) | AstraZeneca | 2019-12-03 |
| A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers (NCT04198558) | AstraZeneca | 2019-11-29 |
| To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia (NCT04155645) | AstraZeneca | 2019-11-21 |
| PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma (NCT04305405) | AstraZeneca | 2019-11-21 |
| A Phase 2b Diabetic Kidney Disease Study (NCT04170543) | AstraZeneca | 2019-11-18 |
| Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions (NCT04184284) | AstraZeneca | 2019-11-15 |
| A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole (NCT04121910) | AstraZeneca | 2019-11-07 |
| Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (NCT04157348) | AstraZeneca | 2019-10-29 |
| A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects (NCT04142424) | AstraZeneca | 2019-10-28 |
| Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer (NCT04052113) | AstraZeneca | 2019-10-25 |
| A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin (NCT04118842) | AstraZeneca | 2019-10-17 |
| A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. (NCT03907969) | AstraZeneca | 2019-10-09 |
| Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics (NCT03953300) | AstraZeneca | 2019-10-08 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers (NCT04076540) | AstraZeneca | 2019-10-03 |
| A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718 (NCT04087187) | AstraZeneca | 2019-09-20 |
| A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. (NCT04072562) | AstraZeneca | 2019-09-19 |
| Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (NCT04008706) | AstraZeneca | 2019-09-17 |
| A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life (NCT04034992) | AstraZeneca | 2019-09-11 |
| Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing. (NCT04078126) | AstraZeneca | 2019-09-10 |
| Durvalumab Long-Term Safety and Efficacy Study (NCT04078152) | AstraZeneca | 2019-09-05 |
| Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE. A Descriptive Analysis of the Asthma Patient Population in the Emirate of Dubai With Respect to Healthcare Resource Utilization, Costs, and Asthma-related Treatment Pattern (NCT03963141) | AstraZeneca | 2019-08-31 |
| An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer (NCT04089553) | AstraZeneca | 2019-08-29 |
| Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (NCT04053634) | AstraZeneca | 2019-08-26 |
| An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (NCT03924635) | AstraZeneca | 2019-08-01 |
| Tezepelumab COPD Exacerbation Study (NCT04039113) | AstraZeneca | 2019-07-30 |
| A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children (NCT03959488) | AstraZeneca | 2019-07-30 |
| Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC (NCT03995875) | AstraZeneca | 2019-07-25 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects (NCT04055168) | AstraZeneca | 2019-07-24 |
| A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma (NCT03976869) | AstraZeneca | 2019-07-24 |
| A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition (NCT04024501) | AstraZeneca | 2019-07-20 |
| Stage III NSCLC RWE in Chinese Patients (NCT04023812) | AstraZeneca | 2019-07-16 |
| A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies (NCT03980821) | AstraZeneca | 2019-07-04 |
| A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (NCT04035486) | AstraZeneca | 2019-07-02 |
| Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (NCT03997123) | AstraZeneca | 2019-06-25 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (NCT03944772) | AstraZeneca | 2019-06-25 |
| A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects (NCT03989544) | AstraZeneca | 2019-06-19 |
| Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma (NCT03927157) | AstraZeneca | 2019-06-14 |
| Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594 (NCT04002427) | AstraZeneca | 2019-06-11 |
| Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS (NCT03918304) | AstraZeneca | 2019-06-11 |
| Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma (NCT04048343) | AstraZeneca | 2019-06-10 |
| Tezepelumab Home Use Study (NCT03968978) | AstraZeneca | 2019-05-21 |
| A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS) (NCT03934333) | AstraZeneca | 2019-05-16 |
| Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients (NCT03931954) | AstraZeneca | 2019-05-15 |
| Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT) (NCT04031898) | AstraZeneca | 2019-05-07 |
| Prevalence of Asthma and Allergies Among Children in UAE (NCT03878680) | AstraZeneca | 2019-04-30 |
| Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (NCT03847428) | AstraZeneca | 2019-04-29 |
| Osimertinib Study in Indian Patients (NCT03853551) | AstraZeneca | 2019-04-18 |
| Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (NCT03875235) | AstraZeneca | 2019-04-16 |
| A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NCT03693300) | AstraZeneca | 2019-04-16 |
| DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction (NCT03877237) | AstraZeneca | 2019-04-09 |
| DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction (NCT03877224) | AstraZeneca | 2019-04-04 |
| Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects (NCT03928262) | AstraZeneca | 2019-04-02 |
| An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (NCT03813407) | AstraZeneca | 2019-04-02 |
| A Disease Registry of Patients With Mantle Cell Lymphoma (NCT03816683) | AstraZeneca | 2019-04-01 |
| SABINA INTERNATIONAL (NCT03857178) | AstraZeneca | 2019-03-29 |
| Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402 (NCT03921268) | AstraZeneca | 2019-03-25 |
| Benralizumab Pregnancy Exposure Study (NCT03794999) | AstraZeneca | 2019-03-20 |
| DAPA - Egypt Study (NCT03624803) | AstraZeneca | 2019-03-09 |
| Durvalumab and Tremelimumab for Pediatric Malignancies (NCT03837899) | AstraZeneca | 2019-03-07 |
| Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (NCT03833154) | AstraZeneca | 2019-03-06 |
| Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin (NCT03608358) | AstraZeneca | 2019-02-27 |
| A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD (NCT03836677) | AstraZeneca | 2019-02-26 |
| A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers (NCT03843060) | AstraZeneca | 2019-02-22 |
| Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (NCT03830866) | AstraZeneca | 2019-02-15 |